Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP)

Research output: Contribution to journalReview articlepeer-review

Abstract

Inhibitors of cholesteryl ester transfer protein (CETP) elevate HDL levels human clinical trials. However, the first CETP inhibitors proved toxic in pivotal trials or showed minimal therapeutic benefit. Anacetrapib showed some clinical benefit but is high lipophilic. This Viewpoint highlights efforts to optimize anacetrapib to a best-in-class CETP inhibitor.

Original languageEnglish (US)
Pages (from-to)13212-13214
Number of pages3
JournalJournal of Medicinal Chemistry
Volume64
Issue number18
DOIs
StatePublished - Sep 23 2021

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP)'. Together they form a unique fingerprint.

Cite this